Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas

摘要: - use of a 2,3-dihydroimidazo[l,2-c]quinazoline compound, or pharmaceutical composition containing same, as sole active agent, combination a) said compound and b) one more fu rther agents, for the preparation medicament treatment prophylaxis non-Hodgkin's lymphoma (NHL), particularly 1st line, 2nd relapsed, refractory, indolent agressive in particular follicular (FL), chronic lymphocytic leukaemia (CLL), marginal zone (MZL), diffuse large B-cell (DLBCL), mantle cell (MCL), transformed (TL), peripheral T-cell (PTCL); combinations further agents; comprising agent biomarkers involved modification expression PI3K isoforms, BTK IKK,, BCR activation, downstream activation NFKB pathway, c-Myc, EZH2, predicting sensitivity and/or resistance cancer patient to providing rationale-based synergistic defined herein increase overcome resistance; method determining level component IKK„ EZH2.